Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant

References

• Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus- host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73:1729–1734.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986;68:119–125.
   PubMed Web of Science ®Google Scholar
• Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062–2068.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers ME, Appelbaum FR, et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant 2011;17:1088–1092.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4 + CD25+ FoxP3 + regulatory T cells. Blood 2005;105: 4743–4748.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25+ Foxp3 + regulatory T cells compared with conventional CD4 + T cells. Blood 2008;111:453–462.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Jim H, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012;97:1882–1889.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Martino R, Parody R, et al. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica 2013;98:526–532.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Haase M, Herbst R, et al. Activity of sirolimus in patients with myelodysplastic syndrome—results of a pilot study. Br J Haematol 2005;128:625–630.
   PubMed Web of Science ®Google Scholar
• Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527–2534.
   PubMed Web of Science ®Google Scholar
• Chan SM, Weng AP, Tibshirani R, et al. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110:278–286.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006;7:285–294.
   PubMedGoogle Scholar
• Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma 2005;46:11–19.
   PubMed Web of Science ®Google Scholar
• Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007;110:490–500.
   PubMed Web of Science ®Google Scholar
• Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012;93:1075–1085.
   PubMed Web of Science ®Google Scholar
• Koenen HJ, Michielsen EC, Verstappen J, et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation 2003; 75:1581–1590.
   PubMed Web of Science ®Google Scholar
• Alyea EP, Li S, Kim HT, et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008;14:920–926.
   PubMed Web of Science ®Google Scholar
• Ho VT, Aldridge J, Kim HT, et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009;15:844–850.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Palmer JM, O’Donnell MR, et al. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leuk Res 2012;36:1152–1156.
   PubMed Web of Science ®Google Scholar
• Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003;102:1601–1605.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Barker JN, Lechner L, et al. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant 2014;20:354–360.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–1633.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011;117:6963–6970.
   PubMed Web of Science ®Google Scholar
• Gineikiene E, Stoskus M, Griskevicius L. Single nucleotide polymorphism-based system improves the applicability of quantitative PCR for chimerism monitoring. J Mol Diagn 2009;11:66–74.
   PubMedGoogle Scholar
• Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855–864.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11: 945–956.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Copelan E, Casper JT, Carter SL, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007;13:1469–1476.
   PubMed Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–170.
   PubMedGoogle Scholar
• Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999;94:1465–1470.
   PubMed Web of Science ®Google Scholar
• Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34 + peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003;17:869–875.
   PubMed Web of Science ®Google Scholar
• Khaled SK, Palmer J, Stiller T, et al. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Bone Marrow Transplant 2013;48:278–283.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Chou JF, Papadopoulos EB, et al. A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. Leuk Lymphoma 2014 Mar 20. [Epub ahead of print]
   Web of Science ®Google Scholar
• Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010;115:1098–1105.
   PubMed Web of Science ®Google Scholar
• Furlong T, Kiem HP, Appelbaum FR, et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008;14:531–537.
   PubMed Web of Science ®Google Scholar
• Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008;112:4425–4431.
   PubMed Web of Science ®Google Scholar
• Shayani S, Palmer J, Stiller T, et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus- host disease prophylaxis. Biol Blood Marrow Transplant 2013;19: 298–304.
   PubMed Web of Science ®Google Scholar
• Cutler C, Logan BR, Nakamura R, et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate for graft-vs.-host disease prophylaxis after HLA-matched, related donor hematopoietic stem cell transplantation: results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Blood 2012;120(Suppl. 1) Abstract 739.
   Google Scholar
• Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012;26:582–588.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114:4919–4927.
   PubMed Web of Science ®Google Scholar
• Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012;119:6145–6154.
   PubMed Web of Science ®Google Scholar
• Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014;15:757–766.
   PubMed Web of Science ®Google Scholar
• Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008;26:5767–5774.
   PubMed Web of Science ®Google Scholar